«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2021年05期

页码:

684-687

栏目:

出版日期:

2021-10-20

文章信息/Info

Title:

-

作者:

秦 樱; 徐兴祥

225001 江苏,大连医科大学,苏北人民医院呼吸内科

Author(s):

-

关键词:

支气管肺癌;  驱动基因;  肺结节;  预后

Keywords:

-

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2021.05.041

摘要:

-

Abstract:

-

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 Chen W, Zhang S, Zou X. Evaluation on the incidence, mortality and tendency of lung cancer in China[J]. Thoracic cancer, 2010, 1(1): 35-40.
3 刘永军, 杨婵婵. 我国肺癌流行趋势及疾病负担概况[J]. 现代商贸工业, 2016, 37(2): 212-213.
4 王 俊, 陈 亮. 肺癌早期基因诊断研究进展[J]. 临床肿瘤学杂志, 2004, 9(4): 431-434.
5 Riquet M, Mordant P, Pricopi C, et al. A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2014, 45(5): 876-881.
6 阚强波, 王俊峰. 手术治疗非小细胞肺癌预后多因素分析[J]. 实用癌症杂志, 2018, 33(1): 75-78.
7 Rajaram P, Chandra P, Ticku S, et al. Epidermal growth factor receptor: Role in human cancer[J]. Indian J Dent Res, 2017, 28(6): 687-694.
8 范力文, 赵 珩. 表皮生长因子受体检测在早期非小细胞肺癌诊治中的研究进展[J]. 临床肺科杂志, 2017, 22(2): 334-339.
9 Ito M, Miyata Y, Kushitani K, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma[J]. Thorac Cancer, 2018, 9(12): 1594-1602.
10 Hayasaka K, Shiono S, Matsumura Y, et al. Epidermal growth factor receptor mutation as a risk factor for recurrence in lung adenocarcinoma[J]. Ann Thorac Surg, 2018, 105(6): 1648-1654.
11 Isaka T, Nakayama H, Ito H, et al. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery[J]. BMC Cancer, 2018, 18(1): 959.
12 Nie Y, Gao W, Li N, et al. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma[J]. World J Surg Oncol, 2017, 15(1): 55.
13 Guerrera F, Renaud S, Tabbo F, et al. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas[J]. Eur J Cardiothorac Surg, 2017, 51(4): 680-688.
14 Dong Y, Li Y, Peng H, et al. Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas[J]. Zhongguo Fei Ai Za Zhi, 2013, 16(4): 177-183.
15 He Q, Xin P, Zhang M, et al.The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures[J]. Transl Lung Cancer Res, 2019, 8(2): 124-134.
16 Takamochi K, Oh S, Matsunaga T, et al. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2017, 154(5): 1768-1774.e1761.
17 Kim YT, Seong YW, Jung YJ, et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer[J]. J Thorac Oncol, 2013, 8(2): 171-178.
18 Du X, Shao Y, Qin HF, et al. ALK-rearrangement in non-small-cell lung cancer(NSCLC)[J]. Thorac Cancer, 2018, 9(4): 423-430.
19 Li P, Gao Q, Jiang X, et al. Comparison of clinicopathological features and prognosis between ALK rearrangements and EGFR mutations in surgically resected early-stage lung adenocarcinoma[J]. J Cancer, 2019, 10(1): 61-71.
20 Shin SH, Lee H, Jeong BH, et al. Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma[J]. J Thorac Dis, 2018, 10(6): 3460-3467.
21 Chaft JE, Dagogo-Jack I, Santini FC, et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer[J]. Lung Cancer, 2018, 122: 67-71.
22 Tao H, Cai Y, Shi L, et al. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma[J]. Thorac Cancer, 2017, 8(1): 8-15.
23 Zhao J, Zhou J, Chen Z, et al. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer[J]. Int J Clin Exp Pathol, 2015, 8(3): 3344-3348.
24 Tomasini P, Walia P, Labbe C, et al. Targeting the KRAS pathway in non-small cell lung cancer[J]. Oncologist, 2016, 21(12): 1450-1460.
25 Izar B, Zhou H, Heist RS, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma[J]. J Thorac Oncol, 2014, 9(9): 1363-1369.
26 Nadal E, Chen G, Prensner JR, et al. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma[J]. J Thorac Oncol, 2014, 9(10): 1513-1522.
27 Renaud S, Falcoz PE, Schaeffer M, et al. Prognostic value of the KRAS G12V mutation in 841 surgically resected caucasian lung adenocarcinoma cases[J]. Br J Cancer, 2015, 113(8): 1206-1215.
28 Seitlinger J, Renaud S, Falcoz PE, et al. Epidermal growth factor receptor and v-Ki-ras2 Kirsten rat sarcoma viral oncogen homologue-specific amino acid substitutions are associated with different histopathological prognostic factors in resected non-small-cell lung cancer[J]. Interact Cardiovasc Thorac Surg, 2016, 23(6): 902-907.
29 Kaseda K, Asakura K, Kazama A, et al. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation[J]. Thorac Cancer, 2017, 8(3): 229-237.
30 Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma[J]. J Thorac Oncol, 2009, 4(1): 22-29.
31 徐陆亭, 赵瑞景, 董增军, 等. 非小细胞肺癌中ROS1基因重排及其临床意义[J]. 中国肺癌杂志, 2013, 16(12): 663-670.
32 Fu S, Liang Y, Lin YB, et al. The frequency and clinical implication of ROS1 and RET rearrangements in resected stage ⅢA-N2 non-small cell lung cancer patients[J]. PLoS One, 2015, 10(4): e0124354.
33 梁小芹, 王 卓, 常守凤, 等. ROS1在肺腺癌组织中的表达及临床意义[J]. 中国癌症防治杂志, 2016, 8(6): 364-368.
34 Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases[J]. Am J Surg Pathol, 2013, 37(4): 554-562.
35 Gould MK, Tang T, Liu IL, et al. Recent trends in the identification of incidental pulmonary nodules[J]. Am J Respir Crit Care Med, 2015, 192(10): 1208-1214.
36 蒋 彬, 孙天宇, 邓 波, 等. 孤立性肺结节良、恶性危险因素分析和外科诊治[J]. 中国胸心血管外科临床杂志, 2016, 23(7): 702-705.
37 Kobayashi Y, Mitsudomi T, Sakao Y, et al. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth[J]. Ann Oncol, 2015, 26(1): 156-161.
38 Kobayashi Y, Ambrogio C, Mitsudomi T.Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights[J]. Transl Lung Cancer Res, 2018, 7(4): 487-497.
39 Wu C, Zhao C, Yang Y, et al. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules[J]. J Thorac Oncol, 2015, 10(5): 778-783.
40 Park E, Ahn S, Kim H, et al. Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules[J]. J Thorac Oncol, 2018, 13(11): 1776-1783.

备注/Memo

备注/Memo:

通信作者: 徐兴祥, Email: xuxx63@sina.com

常用功能

更新日期/Last Update: 2021-10-20